Saad Z. Usmani
Saad Usmani led the pivotal teclistamab study, the first bispecific antibody approved for myeloma.
Myeloma specialist who led MajesTEC-1 (teclistamab) and contributed to daratumumab and cilta-cel programmes; chairs the myeloma service at MSK.
| Title | Journal | Year |
|---|---|---|
| Teclistamab in relapsed or refractory multiple myeloma | New England Journal of Medicine | 2022 |
CEPHEUS extends the quadruplet standard to patients who are not going to transplant, closing the gap between transplant-eligible and ineligible populations. It is also one of the first phase 3 trials to be designed around MRD-negativity as the primary endpoint, which could shorten future myeloma trials by years. Frailer patients still need dose-adapted approaches.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.
Pages like this
not linked directly; found by shared links- TrialMajesTEC-3
Shares Teclistamab, Daratumumab, Multiple myeloma.
- TrialCEPHEUS
Shares CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Daratumumab, Multiple myeloma.
- Key paperMajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma
Shares MajesTEC-1, Teclistamab, BCMA, T-cell engagers (bispecific).
- PairingBCMA-directed therapy → GPRC5D-directed therapy
Shares Teclistamab, BCMA, Multiple myeloma.
- InstitutionComprehensive Cancer Center Mainfranken, University Hospital Würzburg
Shares Teclistamab, BCMA, T-cell engagers (bispecific), Multiple myeloma.
- TrialCARTITUDE-1
Shares CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma, Multiple myeloma.
- Key paperMAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant
Shares CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Daratumumab, Multiple myeloma.
- ProductLinvoseltamab
Shares BCMA, T-cell engagers (bispecific), Multiple myeloma.